Trials / Terminated
TerminatedNCT00372073
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
A Phase IIb Randomized Study of Oral Seliciclib in Patients With Previously Treated Non-Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 187 (actual)
- Sponsor
- Cyclacel Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).
Detailed description
A randomized Phase II study of an experimental anti-cancer drug called seliciclib with objectives of evaluating safety and efficacy in patients with non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | seliciclib | 1200 mg bid x 3 days every 2 weeks |
| DRUG | placebo | 1200 mg bid x 3 days every 2 weeks |
Timeline
- Start date
- 2006-08-09
- Primary completion
- 2009-03-03
- Completion
- 2009-04-07
- First posted
- 2006-09-06
- Last updated
- 2021-12-22
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00372073. Inclusion in this directory is not an endorsement.